Envoy Medical, Inc. — Form 8-K Summary
Reporting date: October 6, 2026; the report was signed October 7, 2026. This is an event filing, not a periodic financial report.
Business context and material event
Envoy Medical entered into a Dismissal Agreement with Atlas Merchant Capital SPAC Fund I LP concerning litigation in the Delaware Court of Chancery. Atlas had alleged that it was not permitted to redeem its Class A common shares in the Company’s September 2023 business combination.
- All Atlas claims will be dismissed with prejudice, and no further proceedings will occur in relation to the litigation.
- Neither Envoy Medical nor any other defendant is required to pay Atlas under the agreement.
Financial information
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics. It does not report financial guidance or an outlook.
Risks, contingencies, and unusual items
The agreement resolves the described litigation without a payment obligation for the Company or other defendants. The filing does not quantify any related legal costs or disclose other financial effects.
Important facts to verify
- Confirm the Dismissal Agreement’s terms and that the claims were dismissed with prejudice.
- Check subsequent filings for any disclosed legal expenses or other financial effects.
- Verify whether any other litigation or contingencies are disclosed elsewhere; this filing addresses only the Atlas litigation.